Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...

Full description

Bibliographic Details
Main Authors: Yang Zheng, Jiayu Zou, Chen Sun, Fu Peng, Cheng Peng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Molecular Biosciences
Subjects:
T-DM1
HER2+
cancer
therapeutic potential
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/full

Similar Items

Similar Items